Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus high-dose interleukin-2 in metastatic melanoma or renal cell carcinoma
2012-001786-32Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jul 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of aldesleukin in melanoma and renal cell carcinoma (RCC) (2 cohorts), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Immunological efficacy and Predictive biomarker value. Started Jul 2012; status: completed.
02
Drugs
aldesleukin
03
Conditions
melanomarenal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2012-001786-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001786-32.